
A-Alpha Bio Inc Profile last edited on: 1/3/22
CAGE: 7ZQ69
UEI: HCTNBH41FKL1
Business Identifier: Cell-based tools for quantitative and high-throughput measurements of protein interactions Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: King
Congr. District: 07
County: King
Public Profile
Organized around the objective of accelerating target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions, A-Alpha Bio has developed a synthetic biology platform designed to aid in the development of drugs that interact with multiple targets. With the firm partnering with pharmaceutical companies to discover and optimize high-impact therapeutics, A=Alpha bio Inc's proprietary synthetic biology platform - designated AlphaSeq - enables screening against thousands of targets in a single experimental step. An all-at-once approach saves time, reduces cost, and improves success rates. The effort is to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 1 | NSF | $256,000 | |
Project Title: Developing a Rapid Antibody Generation Platform for Emerging COVID-19 Variants | ||||
2020 | 2 | NSF | $845,472 | |
Project Title: Developing a Platform for Multiplexed Drug Profiling Using Yeast Synthetic Agglutination |
Key People / Management
David Younger -- Co-Founder and CEO
Randolph Lopez Barrezueta
David Colby -- Principal Scientist
Ryan Emerson -- VP of Data Science
Emily Englehart -- Scientist
Charles Lin -- Engineering Associate
Randolph Lopez -- CTO andFounder
Arpita Sen -- Scientist
Randolph Lopez Barrezueta
David Colby -- Principal Scientist
Ryan Emerson -- VP of Data Science
Emily Englehart -- Scientist
Charles Lin -- Engineering Associate
Randolph Lopez -- CTO andFounder
Arpita Sen -- Scientist